Introduction
Prostate carcinoma (PCa) is the most commonly diagnosed form of invasive cancer in males in the Western world. The growth of prostatic epithelial cells is regulated by several complexes including steroids, growth factors, and cytokines (Culig et al., 2002; Marker et al., 2003) . Androgens particularly regulate prostatic growth through an enhanced cellular proliferation rate (Kimura et al., 2001; Coffey et al., 2002) . The central element of androgen signaling in prostatic cells is the androgen receptor (AR), a member of nuclear receptors (Klocker et al., 1999) . An important early event in the development of the metastatic phenotype is the induction of genes involved in angiogenesis such as vascular endothelial growth factor (VEGF) (Nicholson and Theodorescu, 2004) . VEGF is one of the most potent facilitators in angiogenesis and is expressed by prostatic glandular epithelial cells (Ferrer et al., 1997; Hrouda et al., 2003; Nicholson and Theodorescu, 2004) . VEGF expression has been associated with metastatic capability and overall patient survival in PCa (Borre et al., 2000; Chevalier et al., 2002) , and further, expression of VEGF can be induced by testosterone in animal models (Haggstrom et al., 1999) .
Alterations in the regulation of G1/S phase transition are known to contribute to the formation and progression of various types of tumors including PCa (Hunter and Pines, 1994; Suzuki et al., 2003) . The cell cycle pathways involving the retinoblastoma gene product (Rb) play essential role in cellular proliferation and apoptosis. Alterations in pRb regulatory pathways are tightly associated with malignant transformation (Sherr, 1994 (Sherr, , 1996 . It has been suggested that Rb protein may contribute to the VEGF-mediated vascular formation, as disruption of the interaction between Rb and mitogenic signaling kinase led to the reduction in vessel formation in nude mice (Dasgupta et al., 2004) .
A mammalian A-type cyclin, cyclin A1 is only expressed in several normal tissues including testis, hematopoietic cells and brain (Sweeney et al., 1996; Yang et al., 1997 Yang et al., , 1999 ). An important role for cyclin A1 in hematological malignancies has been demonstrated in a transgenic mouse model, in which targeted overexpression of cyclin A1 in early myeloid cells initiated acute myeloid leukemia (Liao et al., 2001) . Further, the altered subcellular localization of cyclin A1 and the loss of its kinase partner, CDK1 in leukemic cells is linked to the leukemic phenotype (Ekberg et al., 2004) . In male germ cells, cyclin A1 is absolutely required for the meiotic division as demonstrated by gene-targeting (Liu et al., 1998) . Further, elevated levels of cyclin A1 expression have been detected and shown to be associated with formation and progression in male germ cell tumors (CGTs) (Muller-Tidow et al., 2003; Liao et al., 2004) .
Human prostate cancers provide an unique system in which the progression of oncogenic events can be studied by monitoring how cancer cells response to androgenic hormones. Given a critical role of cyclin A1 in tumorigenesis, we wished to establish a role for cyclin A1 in tumor formation and progression of PCa. Further, in view of that VEGF expression is associated with angiogenesis and metastatic capability during tumor progression in PCa (Borre et al., 2000; Chevalier et al., 2002) , we asked whether cyclin A1, a regulatory factor essential for the meiotic division in male germ cells might be involved in the regulation of VEGF expression in prostate cancer. Our initial studies focused on a series of primary prostatic tumors from patients. By employing androgen-sensitive (LNCaP) and androgen-independent (DU-145) prostate cell lines, we further studied the mechanisms by which cyclin A1 is involved in mediating the VEGF expression. Our study suggests that cyclin A1 may contribute to tumorigenesis of prostate cancer.
Results
Cyclin A1 is highly expressed in prostate cancer at aggressive stages and correlates with VEGF Expression of cyclin A1 and its correlation to tumor formation and progression in prostate cancer have not been reported. This prompted us to identify the expression pattern and relative levels of cyclin A1 in a large number of PCa samples. TMAs containing successfully preserved tissue spots from patients with BPH (n ¼ 19) and PCa (n ¼ 96) were examined for the expression of cyclin A1 by immunohistochemical analysis. In BPH samples, only some hyperplastic epithelium revealed positive staining for cyclin A1. The staining signals were apparently weak and were predominantly cytoplasmic (Figure 1, panel a) , suggesting that BPH samples had low levels of cyclin A1 expression. In contrast, virtually all PCa patients had intensive cyclin A1 staining in their tumor cells (Figure 1 , panels b and c). TMAs were also stained with antibody against prostate specific antigen (PSA) to verify the tumor cells (Figure 1 , panels g, h and i). To correlate cyclin A1 expression with tumor progression, we divided 96 PCa into three distinct stages according to the WHO classification: (a) well differentiated, (b) moderately Figure 1 Immunohistochemical analysis of the expression of cyclin A1, VEGF and PSA in PCa specimens. BPH in panels a, d and g, moderately differentiated tumors in panels b, e and h, and poorly differentiated tumors in c, f and i were examined. Cyclin A1 staining is shown in panels a, b and c; VEGF expression is shown in panels d, e and f; and PSA staining is shown in panels c, f and i (Strohmeyer et al., 2000; Chevalier et al., 2002) .
Expression of cyclin A1 and VEGF in prostate specimens and in prostate cancer cells lines
Immunoblot analysis was further performed to verify the expression of cyclin A1 in freshly isolated specimens from PCa patients. Cyclin A1 bands were indeed detected in tumor specimens. Expression of VEGF and Rb protein was also detected in patient samples at equivalent levels to cyclin A1 (Figure 2a ). Cyclin A1 expression was then determined in prostate cancer cell lines including PC-3, DU-145 and LNCaP cells. As expected, cyclin A1 expression was detected in LNCaP cells, an androgen sensitive cell line, but also in PC-3 and DU-145 cells that are androgen insensitive ( Figure 2b ). Assessment of VEGF expression and VEGF secretion in these cell lines by immunoblotting and ELISA analyses demonstrated a similar expression pattern to what was observed for cyclin A1 (Figure 2b and c). Absence of detectable levels of PSA in both PC-3 and DU-145 indicated that these two cell lines do not have functional androgen receptor, AR, in contrast to LNCaP cells.
Increased cyclin A1 expression in LNCaP cells treated with VEGF recombinant protein
Having established a link between the expression of cyclin A1 and VEGF in patient samples, we then asked whether expression of cyclin A1 is regulated by pathways mediated by VEGF. LNCaP cells were cultured in medium containing recombinant human VEGF165 at 1 ng/ml for 24 and 48 h, respectively. A significant increase in cyclin A1 protein expression was observed in suggesting that the action of VEGF may be related to the increased proliferation as was shown by the previous studies (Jackson et al., 2002) . These data indicate that expression of cyclin A1 in LNCaP cells might be regulated by VEGF-mediated pathways.
Increased levels of cyclin A1 and VEGF in LNCaP cells treated with synthetic androgen
Since androgen-mediated pathways play a critical role in prostate cancer, we therefore investigated whether androgen regulates cyclin A1 expression. Treatment of LNCaP cells with R1881, a synthetic androgen, at 0.1, 1 nM concentrations for 72 h resulted in a significant increase in cyclin A1 expression compared to untreated cells ( Figure 4a ). Similar to that of cyclin A1, a pronounced increase in VEGF expression was also observed (Figure 4 ). The increase in cyclin A1 and VEGF expression was more pronounced in cells treated with doses higher than 10 nM R1881 (data not shown).
A slightly upregulation of cyclin A2 and Rb expression was noted in cells treated with 0.1 nM R1881 but not in cells treated with 1 nM R1881 (Figure 4a ). Sandwich ELISA assay further revealed a significant increase in VEGF secretion in cells treated with 1 nM R1881 (Figure 4b ). Analysis of the R1881 signaling on cell proliferation kinetics showed a maximal increase in proliferation rate when cells were treated with 0.1 nM of R1881 (Figure 4c ). However, treatment of LNCaP cells with R1881 at doses higher than 10 nM resulted in a decrease in cell proliferation (data not shown). This suggests that R1881 could promote cell proliferation only to some extent and that the induction of cyclin A1 and VEGF protein by R1881 might not simply be the effect of increased cell proliferation.
Cyclin A1 associated kinase activity on histone H1 and pRb protein significantly increased upon androgen treatment
We further addressed the effect of androgenic hormone R1881 on the ability of cyclin A1/CDKs to phosphorylate their substrates proteins: histone H1 and Rb. The complex formation between cyclin A1 and its specific kinase partners was determined in LNCaP cells by coimmunoprecipitation assay. Detection of the bands corresponding to CDK1 and CDK2 and Rb protein in cyclin A1 immunocomplexes (Figure 5a ) suggested that the complexes between cyclin A1 and CDK1, CDK2 and Rb were present in LNCaP cells. We then investigated the effect of R1881 on the kinase activities of cyclin A1/CDKs in untreated cells and cells treated with R1881 at 0.1 and 1 nM concentrations. As shown in Figure 5b , both histone H1 and Rb were more heavily phosphorylated by cyclin A1/CDKs in cells treated with R1881 than that of untreated cells.
Increased VEGF expression in LNCaP cells overexpressing cyclin A1 after the treatment with R1881
Having identified that VEGF-and androgen-mediated pathways regulate cyclin A1 expression, we then asked whether cyclin A1 in turn is able to regulate VEGF expression in cooperation with androgen action. Expression of cyclin A1 was induced into LNCaP cells by transient transfection. Surprisingly, semiquantitative RT-PCR revealed a significant increase in VEGF mRNA expression in LNCaP cells trasfected with cyclin A1 vector, whereas cyclin A2 mRNA expression remained virtually unchanged (Figure 6a, b) . We then determined whether cyclin A1 was responsible for the transcriptional activity of VEGF gene. As shown in Figure 6c , the ability of cyclin A1 to activate VEGF promoter was observed in LNCaP cells. Interestingly, the level of VEGF activation was significantly manifested in the presence of R1881 (Figure 6c ) suggesting that androgen-mediated pathway cooperates with cyclin A1 to activate VEGF promoter. Further, a significant increase in VEGF secretion was observed in LNCaP cells transfected with cyclin A1 expression vector (Figure 6d ).
Cyclin A1 mediates VEGF expression and promoter activation via Rb-mediated pathways
Since cyclin A1 was able to mediate VEGF expression in the absence and presence of androgen, we then investigated whether Rb-mediated pathway is involved. Induction of cyclin A1 expression in LNCaP cells resulted in a more heavily phosphorylated Rb protein (Figure 6e ). To investigate whether Rb is critical for cyclin A1 action on VEGF, we examined the effect of cyclin A1 expression on the VEGF promoter activation in DU-145 cells that lack a functional Rb. Cyclin A1 expression failed to enhance the expression of VEGF mRNA and VEGF secretion (data not shown) and further, VEGF promoter activation was not affected by cyclin A1 in DU-145 cells (Figure 7a ). Since DU-145 cells also lack a functional AR, we therefore induced AR (1) and cells treated with R1881 at concentrations of 0.1 nM (2) and 1 nM (3) were subjected to kinase assays using histone H1 or Rb as substrates (Figure 7a ). However, coexpression of cyclin A1 and AR did not lead to an increase in VEGF promoter activation, suggesting that despite restoring AR into DU-145 cells in the presence of androgen, cyclin A1 was unable to activate VEGF promoter ( Figure 7a ). Next, we examined the effects of induced expression of Rb, AR and cyclin A1 alone or together on the VEGF promoter activation in the presence or absence of R1881 treatment. Interestingly, induction of Rb expression promoted modestly VEGF promoter activation, coexpresison of cyclin A1 and Rb in DU-145 cells greatly increased VEGF promoter activation (Figure 7b ) suggesting that cyclin A1 need to cooperate with functional Rb to regulate VEGF activation. Coexpression of Rb and AR in the presence of androgen also led to an increased VEGF activation, but to much less extent compared to the effect of coexpression of Rb and cyclin A1 (data not shown). However, when cyclin A1 was coexpressed with Rb and AR altogether in DU-145 cells in the presence of R1881, these factors cooperatively activated VEGF promoter over 100-fold compared to controls (Figure 7b ). Thus, Rb-mediated pathways are most clearly required for cyclin A1 to mediate VEGF promoter activation and further cyclin A1 regulates VEGF expression in cooperation with Rb-and ARdependent pathways.
Discussion
Development and progression of prostate cancer are the multiple-step processes involving the alterations in cell proliferation, apoptosis, angiogenesis, cell migration, invasion (Ali et al., 2001; van Moorselaar and Voest, 2002; Porkka and Visakorpi, 2004) . However, specific factors regulating the formation, progression and metastasis in prostate cancer still remain largely undefined. In the present study, we show that cyclin A1 is highly expressed and correlates with tumor grade in PCa patient samples. We further show that cyclin A1 expression significantly correlates with VEGF expression in PCa patients. Since VEGF has been well established as one of the key regulators in the process of tumor growth and metastatic dissemination (Hicklin and Ellis, 2005) , the positive correlation between cyclin A1 and VEGF in PCa samples is of particularly important for establishing a role for cyclin A1 in prostate cancer. In the present study, we also demonstrate that cyclin A1 regulates VEGF expression in LNCaP cells. More importantly, we show that the cooperation between cyclin A1-, androgen-, and Rbmediated pathways play important role in regulating the autocrine expression of VEGF (Figure 8 ).
We noticed that treatment of LNCaP cells with R1881 at doses lower than 10 nM induced the expression of cyclin A1 and VEGF, in parallel to the increased cellular proliferation. When treated LNCaP cells with R1881 at doses higher than 10 nM continually led to a dosedependent increase in cyclin A1 and VEGF expression, but a decrease in the proliferation. This suggests that the response of cyclin A1 and VEGF to the androgen treatment is androgen-specific, and is not simply dependent on the androgen-induced proliferation. We also detected that there was an increase in cyclin A1/ CDKs activities in response to R1881 treatment. It has been shown that androgen could modulate the progression of tumors by regulating the expression and activities of proteins involved in cellular proliferation (Beato et al., 1995) . It is of interesting to speculate that the increased CDK activities may not only due to the increased cyclin A1 expression, but also due to the altered expression of CDK inhibitors such as p27, p21 and CDK phosphorylation. In the present study, both increased activities of cyclin A1/CDKs upon the treatment of R1881 and upon the induction of cyclin A1 expression allowed phosphorylation of Rb protein.
Moreover, we found a complex formation between cyclin A1 and Rb in LNCaP cells. Our results indicate that there is a physiological interaction between cyclin A1 and Rb protein. We found that cyclin A1 was able to regulate VEGF expression in LNCaP cells, but failed to do so in DU-145 cells that lack functional Rb protein. Reinduced Rb expression to DU-145 cells allowed cyclin A1 to regain its ability to promote VEGF promoter activation. This suggests that there is a tight functional link between cyclin A1 and Rb protein. Firstly, cyclin A1 interacts with Rb protein; Secondly, cyclin A1 regulates VEGF expression in cooperation with Rbdependent pathways. In addition, we found that androgen-mediated pathway, especially androgen receptor AR is important for the action of cyclin A1, and that the Rb protein clearly acts as a bridge between cyclin A1 and AR. Since cyclin A1 was unable to mediate VEGF expression in the absence of a functional Rb, although AR was present. Coexpression of cyclin A1, Rb and AR all together in DU-145 cells in the presence of R1881 significantly increased VEGF promoter activation compared with the effect of coexpression of either cyclin A1 and Rb, or AR and Rb or cyclin A1 and AR. Our results showing the functional link between Rb protein and AR is consistent with the reported studies in which there was a complex formation between Rb and AR, and Rb was required for the AR activity (Lu and Danielsen, 1998) . The ability of cyclin A1 to regulate several important genes that are involved in tumorigenesis has previously been reported. For instance, a forced expression of cyclin A1 resulted in robust induction of wild-type p53 in HNSCC cell lines (Tokumaru et al., 2004) . Cyclin A1 has also been shown to be required for the proliferative effect of Six1, a homeobox protein in cellular proliferation in mammary carcinoma cells (Coletta et al., 2004) . Our study provides additional information on the potential role of cyclin A1 in tumorigenesis. In conclusion, our results suggest that cyclin A1 may contribute to prostate cancer progression by regulating the autocrine expression of VEGF in cooperation with Rb-and AR-dependent pathways.
Materials and methods

Tissues specimens
Patient samples were obtained as archival specimens from Department of Pathology and Department of Urology, Lund University, University Hospital in Malmo¨. Hematoxylin and eosin stained slides of patient specimens were examined for Gleason grading and staged by a National Board certified pathologist (VG). Specimens from benign enlargement of the prostate (BPH) (n ¼ 19), and from 96 PCa including the highly differentiated (n ¼ 15), the moderately differentiated (n ¼ 35) and the poorly differentiated (n ¼ 46) tumors were subjected in duplicates to tissue microarray (TMA) consisting of 1.0 mm in diameter cores mounted in recipient blocks. For immunoblot analysis, tissue specimens from patients with poorly differentiated tumors (n ¼ 3) were obtained after surgical removal. The study was approved by the Ethic's committee, Lund University and the Helsinki Declaration of Human Rights was strictly observed.
Source of antibodies
The following antibodies were used: monoclonal antibody to cyclin A1 (Pharmingene, San Diego, CA, USA); monoclonal antibody to cyclin A2 (Transduction Laboratories, San Jose, CA, USA); monoclonal anti-PSA (code 2E9) as previously described (Lilja et al., 1991) ; monoclonal antibodies to CDK1 and CDK2 (Transduction Laboratories); polyclonal antibody to VEGF, monoclonal antibodies to pRb, phospho-specific pRb and actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunohistochemistry
Expression of cyclin A1, VEGF and PSA in patient samples on TMAs were assessed by immunohistochemical analysis using a semiautomatic diagnostic system (Ventana ES, Ventana Inc., Tucson, AZ, USA) as previously described (Liao et al., 2004) . The specimens were viewed with an Olympus BX51 microscope. The staining signal was graded according to the proportion of positively staining cells (%) and staining intensity on a scale of 0-3. Expression of the proteins in cells was evaluated as positive if the stained cells were distributed in >10% of area. At least 1000 cells were counted and the fraction of positive tumor cells was expressed as a percentage of the total number of cells counted. The cytoplasmic and nuclear staining was recorded separately. The staining intensity was scored as 0 (negative), 1 (weakly positive or positive), 2 (strongly positive) and 3 (very strongly positive).
Cell culture and androgen R1881 treatment
Human prostatic cell lines, LNCaP, DU-145, PC-3 were purchased from American Type Culture Collection (Manassas, VA, USA). For the R1881 treatment, 0.5 Â 10 6 /ml cells were Vascular endothelial growth factor in prostate cancer B Wegiel et al maintained in medium containing charcoal-stripped fetal bovine serum (cFBS) (HyBond) before the treatment as previously described (Taneja et al., 2001) . 0.1, 1, 5, 10, 15 and 20 nM R1881 (Dupont, Boston, MA, USA) dissolved in 70% ethanol were then added into the medium, and cells were collected after 72 h.
Plasmids, transfection and transactivation assay A 1.8 kb full-length human cyclin A1 cDNA cloned into an expression vector pCMS-EGFP (Clonetech, CA, USA) was used. pLuc 2068 reporter vector containing full-length VEGF promoter was a kind gift from Dr. Dieter Marme (Institute of Molecular Medicine, Germany) (Finkenzeller et al., 1997) . The full-length human AR cDNA vector was kindly provided by Dr Shutsung Liao, University of Chicago, IL, USA). The fulllength human Rb cDNA vector was used (Kaelin et al., 1992) . Transient tansfection was performed using the electroporation system with Nucleofection kit (AmaxaBiosystems, Gaithersburg, MD, USA) according to the manufacturer's instructions. In all, 2-10 mg pCMS-cyclin A1-EGFP or pCMS-EGFP control vector were used. In transactivation assay, 100 ng pLuc 2068 reporter vector was used. Luciferase activity was measured using the Luciferase Assay kit (Promega, Madison, WI, USA) following the vendors protocol.
Cell proliferation assay
The effect of synthetic androgen R1881 or rh165 VEGF (Upstate Biotech, New York, NY, USA) on proliferation of LNCaP cells was determined using a nonradioactive BrdUbased cell proliferation assay kit (Roche, Switzerland) according to the manufacturer's protocol. BrdU incorporation into the cellular DNA was determined by measuring the absorbance at 450 nm and 690 nm on an ELISA plate reader.
Immunoblotting, immunoprecipitation and kinase assay
Tissue samples were homogenized and cells were lysed by briefly sonication in ice-cold lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1% NP-40, 10 mM NaF, 10 mM phenylmethylsulfonyl fluoride (PMSF) and the protease inhibitor cocktail Complete Mini (Roche, Basel, Switzerland). Coimmunoprecipitation and kinase assay were performed as described (Ekberg et al., 2004) . In kinase assay, 50 mg/ml calf thymus histone H1 and GST-Rb (Upstate Biotech) were used as substrates.
Sandwich ELISA for VEGF
Production of VEGF in the culture media was measured by using a sandwich ELISA DuoSet kit (R&D Systems, Abingdon, UK) according to the manufacturer's protocol. Briefly, 96-well plates were coated with primary antibody for 6 h and then blocked in 1% BSA and 5% sucrose in PBS at 41C for overnight. Test sample of 100 ml in duplicates were applied and incubated for 2 h. The amplification of signal was achieved by the addition of biotinylated detection antibody. The absorbance was measured at 450 and 690 nm on ELISA plate reader.
RNA isolation and RT-PCR
RNA was prepared with TRIsol s reagent (Total RNA Isolation Reagent) according to the manufacturer's instructions (Life Technologies, Rockville, MD, USA). RNA was reverse transcribed to cDNA following the supplier's protocol (Life Technologies). Primers for human VEGF: 5 0 -CAC CGC CTC GGC TTG TCA CAT-3 0 and 5 0 -CTG CTG TCT TGG GTG CAT TGG-3 0 were previously described (Jozkowicz et al., 2004) . Cyclin A2: 5 0 -AAGAGCGTGAAGATGCCCT-3 0 and 5 0 -GCATTTGGCTGTGAACTACAT-3 0 . GAPDH: 5 0 -AACAGCGACACCCACTCCTC-3 0 and 5 0 -GGAGGGGA GATTCAGTGTGGT-3 0 . The PCR conditions were: denature the DNA at 951C for 5 min, followed by denaturing at 941C for 1 min, then annealing at 551C for 1 min, and extension at 701C for 1 min with 18 cycles using only VEGF or cyclin A2 primers, then with another 17 cycles after the addition of GAPDH primers and finally with the incubation procedure at 701C for 10 min.
Statistical analysis
The Spearman rank correlation test, Mann-Whitney U-test and Student's t-test were used. All statistical analyses were performed using SPSS version 10.0 (SPSS, Chicago, IL, USA).
